A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This literature review assessed the burden of treatment-resistant depression in the United States by compiling published data about the clinical, societal, and economic outcomes associated with failure to respond to one or more adequate trials of drug therapy. METHODS: PubMed and the Tufts Cost-Effectiveness Analyses Registry were searched for English-language articles published between January 1996 and August 2013 that collected primary data about treatment-resistant depression. Two researchers independently assessed study quality and extracted data. RESULTS: Sixty-two articles were included (N=59,462 patients). Patients with treatment-resistant depression had 3.8±2.1 prior depressive episodes and illness duration of 4.4±3.3 years and had completed 4.7±2.7 unsuccessful drug trials involving 2.1±.3 drug classes. Response rates for treatment-resistant depression were 36%±1%. A total of 17%±6% of patients had prior suicide attempts (1.1±.2 attempts per patient). Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response. Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression. CONCLUSIONS: Treatment-resistant depression exacts a substantial toll on patients' quality of life. At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion. These findings underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant.”
In the citing paper
“Among private payers, the mean annual direct healthcare costs per patient for the management of TRD (US$13,196; 2013 GBP8437) were higher than for management of treatment-responsive depression (US$7715; 2013 GBP4933) 14”
In the citing paper
“These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) [15].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [15]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Williams, D. R., González, H. M., Neighbors, H., Nesse, R., Abelson, J. M., Sweetman, J., & Jackson, J. S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.305 · Cited by 1,293
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Research works printed but not linked: 3
- Nierenberg AA, 2001, Journal of Clinical Psychiatry, 62, 5
- Thase ME, 1997, Journal of Clinical Psychiatry, 58, 23
- 1976, Clinical Global Impression (CGI)
Cited by
Items 501–576 of 576
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-makingPreprint
Oemisch, M., & Seo, H. (2023) · eLife · doi:10.7554/elife.87529.1 · Cited by 1
Wu, P.-C., Tsai, S., Chen, T.-J., & Chen, M. (2023) · Taiwanese Journal of Psychiatry · doi:10.4103/tpsy.tpsy_14_23
Forecasting the potential effects of programming combinations for justice-involved youths
Silver, I. A., D’Amato, C., Newsome, J., Johnson, S. L., & Rubenstein, B. Y. (2023) · Journal of Criminal Justice · doi:10.1016/j.jcrimjus.2023.102093 · Cited by 1
Role of ayurvedic herbs in the management of major depressive disorders (MDD)
Rajini, P. S., & Muralidhara, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19084-1.00027-2 · Cited by 2
Lupo, C., Bonetto, G. G., Corral, R. M., Vilapriño, M., Alessandria, H., KANEVSKY, G. A., & Perocco, S. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i161.484 · Cited by 1
Economic Evaluation of Mental Health Interventions
Jin, H., Jalali, A., Wijnen, B. F. M., & Bao, Y. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-3692-6
Alexandre, V., Biscond, M., Leleu, H., Rico, M. S., Hoertel, N., & Llorca, P. (2024) · medRxiv · doi:10.1101/2024.01.18.24301467
Zambrano, J., Hernández, J. L. V., Rigal, F. F. B., de la Serna, L. D. A., KANEVSKY, G. A., & Perocco, S. (2023) · Archivos de Neurociencias · doi:10.31157/an.v1iinpress.634 · Cited by 1
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-makingPreprint
Oemisch, M., & Seo, H. (2024) · eLife · doi:10.7554/elife.87529.2
Utilizing Pharmacogenomics Results to Guide Antidepressant Selection: A Case Report
Vernacchia, N. P., Toro-Pagán, N. M. D., Bardolia, C., & Amin, N. S. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.143 · Cited by 1
Feng, R. (2023) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2023.20.002726
Understanding Treatment Resistance in Depression
Karstensen, V., Olsen, G., & Bastholm, M. (2024) · KMAN Counseling and Psychology Nexus · doi:10.61838/kman.psychnexus.2.1.10
Pain in Seriously Mental Ill Populations
Owen‐Smith, A. A., & Scherrer, J. F. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197649176.003.0022
Ameno, A. C. S., Caron, M. C. A., Campos, A. L. G., Andrade, B. M. M., dos Santos, B. S., Carmozini, D. A. C., Scanavez, G. B., Ghidini, E. F., dos Santos, M. C. R., Albertini, M. E. N., et al. (2024) · Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida · doi:10.36692/xammt965
Gibfried, M., & Grossberg, G. T. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108630344.018
Chapter 20. Vagus Nerve Stimulation and Deep Brain Stimulation
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379620.lg20
Ramasubramanian, V., Mathumathi, S., Thirumalaisamy, G., Ayyanar, S., Rajendhiran, G., & Kannan, M. (2024) · Indian Journal of Psychiatric Nursing · doi:10.4103/iopn.iopn_93_23
Glutamatergic Changes Induced by Stress in the Brain and Effects of Rapid-Acting Antidepressants
Mingardi, J., & Musazzi, L. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_35-1
N1 cassette-lacking NMDA receptors mediate the antidepressant activity of ketaminePreprint
He, A. T., Zhang, W., Li, H., Tu, Y., Lee, D., Kim, D., Jia, Z., Wang, L., & Salter, M. W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.12.648536
“Major depression is a prevalent and debilitating disorder, affecting hundreds of millions of people worldwide and causing tremendous personal and socioeconomic burdens 6,7 .”
Brexpiprazole augmentation and mitochondrial gene expression changes in major depressive disorder
Kondo, K., Yoshino, Y., Kumon, H., Okano, M., Mori, H., Iga, J., & Ueno, S. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251337365
The Current Status of Antidepressant Drugs and the Exploration of New Targets
张, 陈. (2025) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2025.132021
Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression
Clemens, K., Teeple, A., Rive, B., Kirson, N. Y., Desai, U. S., Doran, J., Eid, D., Qu, A., Bowrey, H. E., & Joshi, K. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0092
“Several studies report that adults with TRD have higher rates of relapse, lower rates of remission and disproportionately higher clinical, economic and societal burden than adults with nontreatment resistant MDD or no depression [5–7] .”
Cano-López, J. B., García‐Sancho, E., Ramos‐Cejudo, J., Nordahl, H., & Salguero, J. M. (2025) · Journal of Rational-Emotive & Cognitive-Behavior Therapy · doi:10.1007/s10942-025-00595-0
“Depression is considered one of the principal contributors to incapacity worldwide (Kessler & Bromet, 2013; Mrazek et al., 2014).”
From DNA to Doses: How Pharmacogenomics Transforms Depression Care in Community Pharmacy
Shabana, M., Fatima, N., Teja, T. K., & Zeshan, U. (2025) · Archives of Pharmacy Practice · doi:10.51847/si19cmljuz
“Higher treatment and health care use costs, disability, lost employment, and lower productivity are all indicators that treatment resistance in depressed individuals has major emotional, financial, and social consequences [5].”
Skowron, C. S., Miłkowska, U., Piech, G. M., Lis, I., & Kurzyna, P. F. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0011
Hannah, L. A., Angco, L., Osimo, E. F., Lewis, J. R., Walsh, C. M., & Cardinal, R. N. (2025) · medRxiv · doi:10.1101/2025.07.15.25331272
Glutamatergic Changes Induced by Stress in the Brain and Effects of Rapid-Acting Antidepressants
Mingardi, J., & Musazzi, L. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_35
Epidemiology and Burden of Treatment-Resistant Depression in Colombia: Analysis of the TRAL Study
Cordoba-Rojas, R., Ferro, E., Baena, L. M. A., KANEVSKY, G. A., & Cabrera, P. (2025) · Revista Colombiana de Psiquiatría (English ed ) · doi:10.1016/j.rcpeng.2025.10.007 · Cited by 2
Vasiliu, O., Manchia, M., Noguchi, Y., & Mikellides, G. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1706980
“Such progress was required, and still is, due to the challenges in the clinical domain, where nearly one-third of patients living with severe mental disorders (SMDs) experience some degree of resistance to treatment (1 – 3).”
InfluentialMiller, O. H., Grabole, N., Wells, I., Bellier, L., Nassi, J. J., & Hall, B. J. (2025) · Synapse · doi:10.1002/syn.70033 · Cited by 4
“Depression is the leading psychiatric cause of disability globally (Murray 2012), and first-line therapies targeting the monoamine system are ineffective in a significant population of depressed patients (Mrazek et al. 2014; Rush 2006; Trivedi 2006).”
Chen, L., Thomas, E., & Cerins, A. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-26602-7.00030-0
Treatment-Resistant Depression in Colombia: Results From a Longitudinal Analysis of the TRAL Study
Baena, L. M. A., Cordoba-Rojas, R., Ferro, E., KANEVSKY, G. A., & Perocco, S. (2025) · Revista Colombiana de Psiquiatría (English ed ) · doi:10.1016/j.rcpeng.2025.11.012 · Cited by 1
Derakhshan, D., Lipsman, N., Feinstein, A., LEVITT, A. J., Eizenman, M., Rabin, J. S., & Giacobbe, P. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1696560 · Cited by 1
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19136042
Ni, L., Chen, H., Xu, X., Sun, D., Cai, H., Wang, L., Tang, Q., Hao, Y., Cao, S., & Hu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605388
Ni, L., Chen, H., Xu, X., Sun, D., Cai, H., Wang, L., Tang, Q., Hao, Y., Cao, S., & Hu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605391
Wang, X., Wang, C., Zhang, Y., & An, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22815056
Del Toro-Pagán, N. M., Matos, A., Bardolia, C., Michaud, V., Turgeon, J., & Amin, N. S. (2022) · Figshare · doi:10.6084/m9.figshare.18849369
Wang, X., Wang, C., Zhang, Y., & An, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22815044
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19136048
Jamieson, C., Popova, V., Daly, E., Cooper, K., Drevets, W. C., Rozjabek, H., & Singh, J. B. (2023) · Figshare · doi:10.6084/m9.figshare.22790569
Wang, X., Wang, C., Zhang, Y., & An, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22815059
Wang, X., Wang, C., Zhang, Y., & An, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22815041
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19136045
Del Toro-Pagán, N. M., Matos, A., Bardolia, C., Michaud, V., Turgeon, J., & Amin, N. S. (2022) · Figshare · doi:10.6084/m9.figshare.18849372
Wang, X., Wang, C., Zhang, Y., & An, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22815050
Wang, X., Wang, C., Zhang, Y., & An, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22815053
Prevention of Distress and Despair
Rennebohm, W. C., & Zahniser, J. H. (2026) · Springer eBooks · doi:10.1007/978-3-032-11264-4_7
Integration of Evidence-Based Mental Health Treatment into Primary Care
Zahniser, J. H., & Rennebohm, W. C. (2026) · Springer eBooks · doi:10.1007/978-3-032-11264-4_8
Fan, Y., Sa, R., Ma, R., & Tong, L. (2026) · Health Science Reports · doi:10.1002/hsr2.71747
Dell’Osso, L., Nardi, B., Pronestì, C., Giovannoni, F., Cremone, I. M., Bonelli, C., Pini, S., Fiorillo, A., Paolo, M. D., & Carpita, B. (2026) · International Journal of Social Psychiatry · doi:10.1177/00207640251407182 · Cited by 2
“…legalizing physician-assisted suicide for those suffering from mental illnesses is the fact that some psychiatric illnesses are extremely distressing and do not improve with therapy, indeed it is believed that 12% to 20% of patients with depression are resistant to treatment (Mrazek et al., 2014).”
Case Series of Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Depression
Gue, K. L., & Ting, C. H. (2024) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.20.3.48
“Many different treatment modalities aim to help the patient achieve remission and diminish treatment resistance as TRD has a tremendous effect on the patient’s quality of life and the societal burden is costly (5).”
Boone, L., Shafie, M., Naeem, A., Yang, D., Germann, J., Bai, Y., Goubran, M., Hamani, C., Lipsman, N., Tang, V. M., et al. (2026) · NeuroImage Clinical · doi:10.1016/j.nicl.2026.103976 · Cited by 1
“…comorbidity with other psychiatric conditions – particularly major depressive disorder (MDD) – is common, with lifetime rates estimated as high as 50 – 60% (Denys et al., 2004; Fineberg et al., 2007), contributing to increased morbidity and mortality (Mrazek et al., 2014; Torres, et al., 2025).”
Ketamine induces synaptic and monoaminergic remodeling in human iPSC-derived neuronsPreprint
Sala, C., Pagano, J., Mangano, E., Eminente, S., Marcatili, M., Krivosova, M., Tritto, V., Bordoni, R., Boeckers, T. M., & Conti, L. (2026) · Research Square · doi:10.21203/rs.3.rs-9096293/v1
Rational design, molecular characterization and dissociation mechanisms of PROTACs targeting hFAAH
Xiao, Y., Li, N., 程大志, Cheng, Y., Duan, H., Song, Y., Wang, X., Ou, Z., Luo, T., Shi, H., et al. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp04715c
Pople, C. B., Vasileiadi, M., Zaidi, A., Silver, D., Musa, L., Nyman, A. J., Baskaran, A., Lin, F., Lin, F., Cash, R. F. H., et al. (2026) · medRxiv · doi:10.64898/2026.04.09.26350062
Johansson, R., & Lilliengren, P. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1815946 · Cited by 1
“The burden of TRD is considerable, not only for affected individuals who experience prolonged suffering and functional impairment, but also for healthcare systems facing increased service utilization and costs (5).”
Li, J., Xia, W., Fu, P., Yu, T., & Xue, F. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70568
“Notably, CPGx had no significant effect on the treatment effect at Week 2 of hospitalization, whereas the effect of CPGx on treat-ment outcomes at Week 4 of hospitalization was greater than its effect on treatment outcomes at Weeks 6 and 8.”
Huang, J., Li, Z., Wang, X., Yin, D., Deng, Y., Zheng, Z., Wu, F., jin, C., Jiang, B., & Wang, T. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121904
Meng, H., Yang, Y., Cui, Q., & Long, Z. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.05.024
Martínez‐Gras, I., Molina, J. D. D., Sánchez-Pastor, L., Llamas, S., Espejo-Saavedra, J. M., Compaired, A., Leza, J. C., & Rubio, G. (2026) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2026.100332
Brain–Computer Interfaces: The Dawn of a New Era in Disease Treatment
Feng, Y., Zhang, W., Chen, J., Wu, H., Wu, L., Qiu, Y., Deng, X., Zhu, C., Chen, Y., Zhao, Z., et al. (2026) · Exploration · doi:10.1002/exp.20250452 · Cited by 2
WU, M., Li, A., Meng, K., Yi, Y., Zhang, Z., Shi, C., He, Y., Ouyang, X., Tan, C., & Wan, X. (2026) · BMC Medicine · doi:10.1186/s12916-026-04982-x
“Beyond causing a significant health burden, depression imposes a substantial economic burden on societies [13, 14].”
El impacto de esketamina intranasal en la depresión resistente: 5 años de datos clínicos
González-Pinto, A. (2026) · Psiquiatría Biológica · doi:10.1016/j.psiq.2026.100931
Parks, A. C., Woodward, A. L., Vlisides‐Henry, R. D., Arden, K., Vando, L., Swain, J., & Lamichhane, B. (2026) · Journal of Medical Internet Research · doi:10.2196/92647 · Cited by 1
“Consequently, patients face a costly and demoralizing “roll of the dice” hoping for the right treatment [29].”
DATAd: A new communication and tracking system for treatment-resistant depression
Conroy, S. K., Voytenko, V. L., Docherty, A. R., Quevedo, J., Virk, S., Feifel, D., Parikh, S. V., Bobo, W. V., & Fournier, J. C. J. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122266
Moreira, R., Frade, P., Campeão, N., Gomes, S., Lopes, A. D. M., Lapa, G., Vian, J., Fonseca, A., Polido, F., Barata, B. C., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1749006
“Furthermore, evidence suggests patients with TRD experience increased disease burden compared to their treatment-responsive counterparts, placing additional strain on clinical management (5, 9 – 13).”
Li, T., Zhang, L., Han, Y., Guo, Z., Yao, P., Chen, L., Yuan, Y., Zhao, J., Ou, Y., Lv, D., et al. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e01091
Hough, C. M., Kruse, J. L., Espinoza, R. T., Brooks, J. O., Congdon, E. L., Norris, V., Craske, M. G., & Narr, K. L. (2026) · Journal of Ect · doi:10.1097/yct.0000000000001338
Kawase, K. (2026) · Pediatrics International · doi:10.1111/ped.70574
“Adult psychiatric disorders, like childhood NDDs, substantially impair the quality of life of affected individuals and their families and impose considerable social and economic burdens [22].”
Zito, M. F. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551517.lg18
Navigating the Complexities of Treatment-Resistant Depression in Late Life
Cross, C. B., Hristidis, V. C., & Lenze, E. J. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260010
Szawarnoga, D., Fojcik, J., Górski, M. K., & Krzystanek, M. (2026) · Pharmaceuticals · doi:10.3390/ph19101644
Severtson, S. G., Boskovic, D. H., Marci, C. D., Eisenberg, D. F., Abdrabboh, A., & Ardic, F. C. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01029-4 · Cited by 1
Metadata
- Authors
- Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I.
- Affiliations
- Mayo Clinic (US)
- Venue
- Psychiatric Services
- Published
- 2014-08
- Volume
- 65
- Issue
- 8
- Pages
- 977-987
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2111118992
- Cited by
- 580
- References
- 80
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 37 · 2023: 76 · 2022: 62 · 2021: 78 · 2020: 64 · 2019: 66 · 2018: 49 · 2017: 28 · 2016: 23 · 2015: 19 · 2014: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, economic burden, social burden, quality of life, health care costs, productivity loss, treatment response rate, suicide attempts, disease duration, major depressive disorder
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Humans, Quality of Life, Cost of Illness, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.